Tullett Prebon Considering Buying Icap’s Global Broking Business

Both firms confirm in statements that they are in talks.

business-deal-handshake-graphic
Tullett Prebon is in talks with Icap to buy its global broking business.

Icap’s associated technology and broking platforms would be sold to Tullett Prebon as part of the deal, according to the statements.

Tullett Prebon would issue new shares to Icap’s shareholders, giving Icap a minority stake in Tullett Prebon.

Both sides were very clear in their statements that nothing has been confirmed.

“There can be no certainty that these discussions will lead to any transaction or as to the terms upon which any such transaction might proceed,” Icap said in a statement.

Tullett Prebon had a similar sentiment.

“Discussions regarding the transaction are currently ongoing and there can be no certainty that any transaction will be agreed. Tullett Prebon will update the market when it is appropriate to do so,” Tullett Prebon said in a statement. 

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Systematic tools gain favor in fixed income

Automation is enabling systematic strategies in fixed income that were previously reserved for equities trading. The tech gap between the two may be closing, but differences remain.

Why recent failures are a catalyst for DLT’s success

Deutsche Bank’s Mathew Kathayanat and Jie Yi Lee argue that DLT's high-profile failures don't mean the technology is dead. Now that the hype has died down, the path is cleared for more measured decisions about DLT’s applications.

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here